Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter ended June 30, 2021 (Q1 FY22)
Filing Date: July 27, 2021
This filing serves as a disclosure of results of operations and financial condition. The registrant has furnished the SEC with press releases and unaudited consolidated financial results prepared under both International Financial Reporting Standards (IFRS) and Indian Accounting Standards (Ind AS).
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity.
Available Data: None. The filing references attached exhibits (99.1 through 99.4) which contain the actual financial figures, but the text of the Form 6-K itself does not list these values.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) and financial statements (Exhibits 99.2 and 99.3) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The text confirms the issuance of a press release and financial results but does not include specific management commentary, forward-looking guidance, or risk factors within this document.
Unusual Items: No unusual items are described in the cover text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue and profit figures for Q1 FY22.
- Compare Exhibit 99.2 (IFRS results) and Exhibit 99.3 (Ind AS results) to understand accounting standard differences.
- Verify year-over-year growth rates and margin trends in the attached financial statements, as they are not summarized in this filing.
- Check the company website (www.drreddys.com) for the full text of the press release and detailed financial tables.